Increased sensitivity of canine sarcoma cells to lysis with alloantiserum and complement after pretreatment of cells with doxorubicin HC1.
The 51Cr release assay was used to detect lysis of canine sarcoma cells incubated in vitro with alloantiserum and complement. Preincubation of the target cells with the anti-cancer agent doxorubicin-HCl increased the sensitivity of the cells to antibody-mediated lysis. The effect was dependent upon drug dose and was not reproduced by treatment with methotrexate, cytarabine, or dactinomycin. The observation suggests a possible ancillary mode of action for doxorubicin-HCl on neoplastic cells.
D000818:Animals; D000937:Antigen-Antibody Reactions; D003165:Complement System Proteins; D003601:Cytotoxicity Tests, Immunologic; D004285:Dogs; D004317:Doxorubicin / Q000494:pharmacology*; D007106:Immune Sera; D066298:In Vitro Techniques; D008297:Male; D012509:Sarcoma / Q000276:immunology*
D007106:Immune Sera; D004317:Doxorubicin; D003165:Complement System Proteins